CREST syndrome

CREST syndrome
Other names: Calcinosis-Raynaud phenomenon-esophageal involvement-sclerodactyly-telangiectasia syndrome[1]
CREST syndrome (calcinosis and sclerodactyly)
SpecialtyRheumatology

CREST syndrome, also known as the limited cutaneous form of systemic sclerosis (lcSSc), is a multisystem connective tissue disorder. The acronym "CREST" refers to the five main features: calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia.[2]

CREST syndrome is associated with detectable antibodies against centromeres (a component of the cell nucleus), and usually spares the kidneys (a feature more common in the related condition systemic scleroderma). If the lungs are involved, it is usually in the form of pulmonary arterial hypertension.

Signs and symptoms

  • Indurated, slightly erythematous plaques on bilateral lower leg
    Indurated, slightly erythematous plaques on bilateral lower leg
  • CREST syndrome (calcinosis and sclerodactyly)
    CREST syndrome (calcinosis and sclerodactyly)

Calcinosis

CREST causes thickening and tightening of the skin with deposition of calcific nodules ("calcinosis").

Raynaud's phenomenon

Raynaud's phenomenon is frequently the first manifestation of CREST/lcSSc, preceding other symptoms by years. Stress and cold temperature induce an exaggerated vasoconstriction of the small arteries, arterioles, and thermoregulatory vessels of the skin of the digits. Clinically this manifests as a white-blue-red transition in skin color. Underlying this transition is pallor and cyanosis of the digits, followed by a reactive hyperemia as they rewarm.[3] When extreme and frequent, this phenomenon can lead to digital ulcerations, gangrene, or amputation. Ulceration can predispose to chronic infections of the involved site.

Esophageal dysmotility

Presents as a sensation of food getting stuck (dysphagia) in the mid- or lower esophagus, atypical chest pain, or cough. People often state they must drink liquids to swallow solid food. This motility problem results from atrophy of the gastrointestinal tract wall smooth muscle.[3] This change may occur with or without pathologic evidence of significant tissue fibrosis.

Sclerodactyly

Though it is the most easily recognizable manifestation, it is not prominent in all patients. Thickening generally only involves the skin of the fingers distal to the metacarpophalangeal joints in CREST. Early in the course of the disease, the skin may appear edematous and inflamed. Eventually, dermal fibroblasts overproduce extracellular matrix leading to increased tissue collagen deposition in the skin. Collagen cross-linking then causes a progressive skin tightening. Digital ischemic ulcers commonly form on the distal fingers in 30–50% of patients.[3]

Telangiectasias

Marked telangiectasias (dilated capillaries) occur on the skin of the face, the palmar surface of the hands, and the mucous membranes. Telangiectasias tend to be more numerous in people with other scleroderma related vascular disease (i.e., pulmonary arterial hypertension). The number of telangiectasias and the sites involved tend to increase over time.[3]...

Other

Other symptoms of CREST syndrome can be exhaustion, weakness, difficulties with breathing, pain in hands and feet, dizziness and badly healing wounds.

Patients with lcSSc commonly induce pulmonary artery hypertension which may result in cor pulmonale (heart failure due to increased pulmonary artery pressure).

Cause

CREST syndrome involves the production of autoimmune anti-nuclear and anti-centromere antibodies, though their cause is not currently understood. There is no known infectious cause.

Diagnosis

CREST is not easily diagnosed as it closely mimics symptoms of other connective tissue and autoimmune diseases. Diagnoses are usually given when a patient presents two or more of the five major clinical symptoms.[4] Additionally, blood exams can be given to test for a positive ANAs and ACAs or skin biopsies can be given to help confirm a diagnosis.[5]

  • Main antinuclear antibody patterns on immunofluorescence. CREST syndrome typically displays the centrome pattern.
    Main antinuclear antibody patterns on immunofluorescence.[6] CREST syndrome typically displays the centrome pattern.
  • X-rays showing calcinosis in a woman with CREST syndrome
    X-rays showing calcinosis in a woman with CREST syndrome
  • X-ray of subtle calcifications in CREST syndrome
    X-ray of subtle calcifications in CREST syndrome

Treatment

Disease progression may be slowed with immunosuppressives and other medications, and esophageal reflux, pulmonary hypertension and Raynaud phenomenon may benefit from symptomatic treatment. However, there is no cure for this disease as there is no cure for scleroderma in general.

Epidemiology

CREST syndrome can be noted in up to 10% of patients with primary biliary cholangitis.[7]

History

The combination of symptoms was first reported in 1964 by R.H. Winterbauer, at that point a medical student at Johns Hopkins School of Medicine.[2]

See also

References

  1. ↑ RESERVED, INSERM US14-- ALL RIGHTS. "Orphanet: CREST syndrome". www.orpha.net. Archived from the original on 3 August 2019. Retrieved 27 April 2019.
  2. 1 2 Winterbauer RH (1964). "Multiple telangiectasia, Raynaud's phenomenon, sclerodactyly, and subcutanious calcinosis: a syndrome mimicking hereditary hemorrhagic telangiectasia". Bulletin of the Johns Hopkins Hospital. 114: 361–83. PMID 14171636.
  3. 1 2 3 4 Hummers, L.K. "CURRENT Rheumatology Diagnosis & Treatment, 3e". New York: McGraw-Hill. Archived from the original on 2019-12-04. Retrieved 2014-02-20.
  4. ↑ "CREST syndrome: MedlinePlus Medical Encyclopedia Image". medlineplus.gov. Archived from the original on 2023-08-29. Retrieved 2023-08-13.
  5. ↑ "CREST syndrome - Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Archived from the original on 2018-07-20. Retrieved 2017-12-05.
  6. ↑ Al-Mughales JA (2022). "Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters". Front Immunol. 13: 850759. doi:10.3389/fimmu.2022.850759. PMC 8964090. PMID 35359932.
  7. ↑ Talwalkar, JA; Lindor, KD (Jul 5, 2003). "Primary biliary cirrhosis". Lancet. 362 (9377): 53–61. doi:10.1016/S0140-6736(03)13808-1. PMID 12853201. S2CID 32716419.
Classification
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.